Wells Fargo & Company Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $75.00
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target lowered by stock analysts at Wells Fargo & Company from $100.00 to $75.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target lowered by stock analysts at Wells Fargo & Company from $100.00 to $75.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside […]
